KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.
Ravindra Uppaluri(Brigham and Women's Hospital), Douglas R. Adkins(Washington University in St. Louis), Stéphane Temam(Institut Gustave Roussy), Sufia Safina(Republican Oncological Clinical Dispensary), Rebecca D. Chernock(Washington University in St. Louis), William H. Westra(Mount Sinai Hospital), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Behzad Bidadi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christophe Le Tourneau(Institut Curie), Amichay Meirovitz(Hadassah Medical Center), Irene Braña(Vall d'Hebron Institute of Oncology), Robert I. Haddad(Georgetown University), Ezra E.W. Cohen(Moores Cancer Center), Joy Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), A L Klochikhin
Cited by 51
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k